Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of REMD-477 in Type 2 Diabetes
NCT02455011Phase 2Completed
- Sponsor
- REMD Biotherapeutics, Inc.
- Start
- Sep 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of volagidemab in type 2 diabetes mellitus (T2DM), sponsored by REMD Biotherapeutics, Inc.. Started Sep 2015; status: completed.
02
Drugs
volagidemab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02455011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02455011.